Back to top
more

Insulet (PODD)

(Real Time Quote from BATS)

$320.31 USD

320.31
366,724

-11.82 (-3.56%)

Updated Sep 17, 2025 11:30 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (87 out of 245)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Invest in Penumbra (PEN) Stock Now

by Zacks Equity Research

Investors are optimistic about Penumbra (PEN), which is led by growth in vascular and neuro businesses.

Zacks Equity Research

Align's (ALGN) Invisalign Palatal Expander System Gets FDA Nod

by Zacks Equity Research

Align's (ALGN) Invisalign Palatal Expander is the company's first direct 3D-printed orthodontic device. It offers a safe, pleasant and clinically effective alternative to traditional palatal expanders.

Zacks Equity Research

CVS Health (CVS) New Opportunities Drive Growth, Macro Woes Stay

by Zacks Equity Research

CVS Health's (CVS) restructuring plan poises it well, along with its strategic buyouts.

Zacks Equity Research

SenesTech (SNES) Likely to Expand Into China With New Deal

by Zacks Equity Research

This partnership provides SenesTech (SNES) with a gateway into one of the largest pest control markets globally, with the support and expertise of Fruit Tree.

Nalak Das headshot

5 Nasdaq Composite Laggards Likely to Gather Pace in 2024

by Nalak Das

We have narrowed our search to five Nasdaq Composite listed laggards of 2023 with strong potential for 2024. These are: PEP, KHC, WMG, PODD, BGNE.

Zacks Equity Research

Charles River's (CRL) Memphis Site Achieves Crucial Approval

by Zacks Equity Research

Charles River (CRL) reaches an important milestone in cell therapy manufacturing collaboration with Vertex Pharmaceuticals.

Zacks Equity Research

Here's Why You Should Retain Tandem Diabetes (TNDM) Now

by Zacks Equity Research

Investors remain optimistic about Tandem Diabetes (TNDM), backed by the impressive spree of product introductions.

Zacks Equity Research

Abbott (ABT) Gains From Global Expansion Amid Macro Woes

by Zacks Equity Research

Abbott's (ABT) EPD business continues to witness low double-digit growth. It has successfully positioned itself as one of the best-positioned large healthcare companies in emerging markets.

Zacks Equity Research

Thermo Fisher (TMO) to Allocate IFA Testing Kits With New Pact

by Zacks Equity Research

Thermo Fisher (TMO) will continue to meet the evolving needs of laboratories and healthcare professionals by expanding its immunology product portfolio of EliA autoimmune diagnostics.

Zacks Equity Research

Quest Diagnostics' (DGX) Haystack Oncology Inks New Deal

by Zacks Equity Research

Quest Diagnostics' (DGX) wholly owned subsidiary, Haystack Oncology, partners with the Rutgers Cancer Institute of New Jersey.

Zacks Equity Research

Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now

by Zacks Equity Research

Investors continue to be optimistic about IDEXX (IDXX), backed by the strength of the CAG Diagnostics business.

Zacks Equity Research

Here's Why You Should Retain Hologic (HOLX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Hologic (HOLX), which is led by growth with recovery in procedural volumes and acceleration from new business lines.

Zacks Equity Research

Here's Why You Should Retain Globus Medical (GMED) Stock Now

by Zacks Equity Research

Investors are optimistic about Globus Medical (GMED) on growing demand for musculoskeletal devices and its strong solvency position.

Zacks Equity Research

Neogen (NEOG) to Advance Feline DNA Testing With New Pact

by Zacks Equity Research

Neogen's (NEOG) strategic alliance will expand feline DNA testing and strengthen its relationship with the kitty community.

Zacks Equity Research

Align's (ALGN) New Launches Aid, Macroeconomic Woes Linger

by Zacks Equity Research

Align Technology (ALGN) performs digital treatment planning and interpretation for restorative cases worldwide, including Costa Rica, China, Germany, Spain, Poland and Japan, among others.

Zacks Equity Research

Align Technologies (ALGN) Secures Updated Medical Device License

by Zacks Equity Research

Align Technologies' (ALGN) Invisalign Palatal Expander system receives an updated medical device license from Health Canada.

Zacks Equity Research

Here's Why You Should Buy Neogen (NEOG) Stock Now

by Zacks Equity Research

Investors are optimistic about Neogen (NEOG), owing to product launches and the performance of segments.

Zacks Equity Research

Tandem Diabetes (TNDM) Avails Tandem Source in the United States

by Zacks Equity Research

Tandem Diabetes (TNDM) announces the full U.S. launch of Tandem Source, a new diabetes management platform for customers and healthcare providers.

Zacks Equity Research

Integra (IART) to Advance ENT Division With New Buyout Deal

by Zacks Equity Research

Integra (IART) will be among the top suppliers of ENT products and technologies following the Acclarent acquisition.

Zacks Equity Research

Myriad Genetics' (MYGN) New Partnerships Aid Amid FX Woes

by Zacks Equity Research

Myriad Genetics (MYGN) continues to record strong revenue growth from companion diagnostics, including significant revenue share from its proprietary myChoiceCDx test.

Zacks Equity Research

Medtronic (MDT) Expands AI-Driven Care With New Partnership

by Zacks Equity Research

Medtronic's (MDT) expanded collaboration with Cosmo Pharmaceuticals is a strategic step forward in its quest to use AI to improve patient care.

Zacks Equity Research

Here's Why You Should Retain Exact Sciences (EXAS) Stock Now

by Zacks Equity Research

Investors are optimistic about Exact Sciences (EXAS) on strong Cologuard adoption and raised guidance.

Zacks Equity Research

Is Insulet (PODD) a Solid Growth Stock? 3 Reasons to Think "Yes"

by Zacks Equity Research

Insulet (PODD) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Equity Research

QIAGEN's (QGEN) Strategic Alliances Aid Amid Macro Woes

by Zacks Equity Research

QIAGEN (QGEN) aims to expand the NGS platform by rapidly scaling up the new Enterprise Genomics Services.

Zacks Equity Research

Terumo (TRUMY) Launches AZUR HydroPack in Embolotherapy Space

by Zacks Equity Research

Terumo's (TRUMY) coil system boasts a soft, universal-shaped platinum and hydrogel composition, which sets it apart in the peripheral coil market.